SPARC logo

Sun Pharma Advanced Research Company Limited Stock Price

NSEI:SPARC Community·₹45.3b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

SPARC Share Price Performance

₹0
-155.47 (-100.00%)
₹0
-155.47 (-100.00%)
Price ₹0

SPARC Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Low risk with imperfect balance sheet.

3 Risks
0 Rewards

Sun Pharma Advanced Research Company Limited Key Details

₹596.0m

Revenue

₹285.9m

Cost of Revenue

₹310.1m

Gross Profit

₹3.0b

Other Expenses

-₹2.7b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 09, 2026
-8.23
52.03%
-448.02%
-119.1%
View Full Analysis

About SPARC

Founded
2006
Employees
316
CEO
Anilkumar Raghavan
WebsiteView website
sparc.life

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Recent SPARC News & Updates

Recent updates

No updates